GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response (NCT04387201), a non-randomized phase 4 study. The primary outcome is Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue).

2. Clinical Question

The study’s broader rationale concerns whether GLP-1 signaling is associated with IL-6 secretion and changes related to brown fat formation. The outcome is a molecular measure in adipose tissue rather than a direct measure of body weight, glucose control, or a clinical event. The registry also lists secondary measures involving adipose tissue and peripheral blood mononuclear cells, but their results are not reported in the registry record.

3. Trial Design

This is a Phase 4, non-randomized crossover study with no masking. Enrollment was 23, and the registry status is completed. The listed study dates are 2020-05-15 for start and 2023-10-06 for primary completion. These dates describe the record; they do not establish when results were analyzed or posted.

The record describes two treatment sequences. In one, participants received cyanocobalamin 1000 mcg subcutaneously weekly for 6 weeks, had a 3-week washout, and then received dulaglutide 0.75 mg weekly for 2 weeks followed by 1.5 mg weekly for 4 weeks. In the other sequence, the dulaglutide schedule came first, followed after a 3-week washout by cyanocobalamin 1000 mcg weekly for 6 weeks. The registry wording does not establish whether every enrolled participant completed both periods.

In a crossover design, each participant can contribute measurements during more than one intervention period. This can allow within-person comparisons, which may account for stable differences between participants. However, interpretation depends on how the treatment sequence, period effects, and possible carryover are handled. The registry record does not report the analysis method for those issues. Because allocation was non-randomized and masking was none, differences between sequences or expectations about treatment could also affect interpretation.

The registry lists the primary measurement time as 6 weeks after the start of each intervention. It does not report a statistical analysis plan, the precise analysis population, exclusions, or whether the primary comparison was made within participants or between sequence groups. The posted record therefore identifies the study structure and intended outcome but does not provide enough information to reconstruct the primary analysis.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

First Intervention (6 Weeks)

Washout (3 Weeks)

Second Intervention (6 Weeks)

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue), measured over 6 weeks after start of each intervention.

The primary endpoint is the cytokine interleukin-6 (IL-6) messenger ribonucleic acid (mRNA) level from adipose tissue. It is reported on a natural log scale in arbitrary units, with the outcome type described as a mean and the dispersion specified as a 95% confidence interval. The stated timeframe is 6 weeks after the start of each intervention. The registry says that natural log-transformed data are reported.

IL-6 is a cytokine, and the study rationale concerns a possible relationship between GLP-1 treatment, IL-6 signaling, and adipose tissue remodeling. Measuring mRNA in adipose tissue addresses gene expression in the sampled tissue. It is not the same measurement as circulating IL-6 protein, nor does it directly measure brown fat formation or a clinical metabolic outcome. The listed secondary outcomes include additional adipose tissue markers and measures from peripheral blood mononuclear cells.

In general, a mean summarizes the central value of a continuous measurement, while a confidence interval communicates uncertainty around an estimate under the analysis assumptions. A natural log scale expresses the endpoint after logarithmic transformation; interpretation should therefore be tied to the reported scale and analysis. The registry record does not report the mean values, confidence interval bounds, or a treatment contrast, so the size and direction of any endpoint difference cannot be assessed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary outcome as a continuous measure summarized by a mean and a 95% confidence interval. However, it does not report the endpoint estimates or identify the exact statistical test or model. The statistical discussion below is general; it explains how these methods are usually interpreted and does not assert that a particular unreported method was used.

What does a mean describe?

For a continuous endpoint, the mean is a measure of central tendency. It gives a summary of the observed values on the scale being analyzed. Here, the registry specifies natural log-transformed IL-6 mRNA in arbitrary units. The mean therefore pertains to the transformed scale, not directly to an untransformed concentration. The record does not provide the mean for either intervention period or a mean difference between periods.

What does a confidence interval convey?

In general, a confidence interval describes the statistical uncertainty around an estimated quantity under the assumptions of the method used. A narrower interval indicates greater precision than a wider interval, but precision alone does not establish clinical importance or freedom from bias. The registry specifies a 95% confidence interval for the primary outcome, but its bounds are not reported in the registry record. Without those bounds and the estimate they accompany, the precision cannot be evaluated.

Why does the crossover structure matter?

In general, a crossover study measures participants during more than one intervention period. A within-person analysis compares measurements from the same participant, potentially reducing variability due to stable characteristics. The validity of that comparison depends on the design and analysis: outcomes may change over time, the first intervention may affect measurements in a later period, and sequence may matter. The registry lists a 3-week washout between interventions but does not report whether carryover was assessed or how period and sequence effects were modeled. A washout period by itself does not establish that carryover was absent.

Allocation is described as non-randomized, and masking as none. These features do not rule out a useful descriptive comparison, but they leave potential for systematic differences or expectation effects. The record does not explain how sequence allocation occurred, whether participants or assessors knew the intervention, or whether any protections against bias were used.

What does the sample-size illustration represent?

In general, sample-size planning describes how many participants may be needed under stated assumptions to detect a target effect with specified statistical properties. The registry’s planning assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a stated fraction of an observed effect. These are planning assumptions, not evidence of the trial’s original design rationale. The record does not report a sample-size justification for the trial. Any planning illustration is not observed power and does not reveal the precision of the actual endpoint estimate.

The registry characterizes the trial as crossover, while the planning assumptions refer to equal allocation between two arms and a normal approximation. Those assumptions should not be taken as a description of the primary crossover analysis. The record does not report whether the illustration accounts for within-person correlation, period effects, or the sequence structure. Its numerical planning outputs are not reported in the registry record.

What can be inferred from the analysis listing?

The record lists zero analyses. This indicates that no analysis entries are listed in the registry record; it does not establish whether analyses were conducted outside the record or explain how the endpoint was handled. The exact model, test, covariates, treatment of repeated observations, and handling of missing data are not reported in the registry record. Without these details, an independent reader cannot reproduce the intended inferential procedure from the registration information.

For any reported estimate, a useful statistical reading would distinguish the estimated effect from its uncertainty and would consider whether the analysis matches the crossover design. The registry record does not contain the numerical results needed to make that assessment for IL-6 mRNA.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 25 outcome measures and identifies one primary endpoint, with several secondary molecular outcomes described. When a study evaluates multiple outcomes or comparisons, the chance of at least one apparently unusual result can increase if each is tested separately without a plan for multiplicity. In general, multiplicity procedures can control error rates or prioritize a prespecified primary analysis. The registry record does not report a multiplicity strategy, a hierarchy among secondary outcomes, or which comparisons were included in any adjustment.

The record lists zero analyses. It does not report an analysis population, participant flow for the endpoint, missing-data counts, reasons for missingness, or a method for handling incomplete measurements. These omissions prevent assessment of whether the endpoint analysis included all eligible participants, only those with complete measurements, or another defined group. They also prevent evaluation of whether missingness could have affected the estimate.

For a crossover study, it would be important to know how paired observations were treated and whether participants with data from only one period were included in any analysis. The registry record does not report these details. It also does not report a prespecified statistical analysis plan or the handling of period, sequence, or carryover effects.

These are reporting gaps, not proof that no multiplicity or missing-data methods were used. Since the primary outcome results are not reported in the registry record, their effect on the interpretation cannot be evaluated.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry lists serious adverse events for both intervention groups. For cyanocobalamin, the number at risk for serious adverse events is 23, the number affected is 0, the number at risk for other adverse events is 23, and the number affected by other adverse events is 1. For dulaglutide, the corresponding figures are 23 at risk and 0 affected for serious adverse events, and 23 at risk and 0 affected for other adverse events. Deaths are listed as 0 for each group.

These are the registry’s group-level counts and should be read as recorded, not as a randomized comparison. Allocation was non-randomized, masking was none, and the study used a crossover design. The record does not give event descriptions beyond the listed categories, exposure-adjusted rates, confidence intervals, or a statistical comparison. It also does not clarify in the adverse-event listing how events occurring across crossover periods were attributed to groups.

In general, a count of zero observed events does not prove that risk is absent, particularly when the amount of exposure and uncertainty are not described. These figures are a safety summary in the registry record, not evidence by themselves of a comparative safety difference.

12. What the Result Does, and Does Not, Mean

The record establishes that investigators studied adipose tissue IL-6 mRNA in a Phase 4, non-randomized crossover study of dulaglutide and cyanocobalamin. It specifies the intervention schedules, a washout period, and a measurement time of 6 weeks after the start of each intervention. It also identifies secondary molecular outcomes and includes group-level adverse-event counts.

What the record does not establish is whether IL-6 mRNA increased or decreased, how large any difference was, or how precisely it was estimated. Numerical primary endpoint results, confidence interval bounds, and an inferential comparison are not reported in the registry record. It is therefore not possible to conclude from this record whether the endpoint differed between the intervention periods.

The endpoint is a molecular measure, not a direct measure of clinical benefit or harm. Even a clear difference in adipose tissue mRNA would not, on its own, demonstrate a change in a clinical outcome or establish the biological pathway proposed in the study rationale. Additional outcomes, methods, and evidence would be required to connect this marker to broader metabolic effects.

The crossover design may permit within-person comparisons, but allocation was non-randomized and masking was none. The registry does not report how the analysis addressed period, sequence, or carryover effects, nor does it describe missing data or the analysis population. Those uncertainties constrain causal interpretation.

The posted adverse-event counts show no listed serious adverse events or deaths in either group, and the listed count for other adverse events is one in the cyanocobalamin group and zero in the dulaglutide group. Given the limited detail and absence of a reported comparative analysis, those counts should not be read as establishing a safety difference or absence of risk.

13. Why This Trial Matters Statistically

This study raises a statistical question about how to interpret a biomarker measured in adipose tissue across intervention periods. The crossover structure is relevant because measurements may be paired within participants, and that pairing can affect both the analysis and the precision of an estimate. At the same time, period, sequence, and carryover effects need consideration. The registry identifies the structure but does not report how these features were analyzed.

The endpoint is reported on a natural log scale, which makes the analysis scale important. Statistical summaries on a transformed scale should not be casually treated as though they were measurements on the original scale. The registry describes the scale and summary type but does not provide the estimates needed to understand the observed response.

The record also illustrates a distinction between a registered question and an interpretable result. A completed study and a named primary endpoint do not supply an effect estimate, its uncertainty, or enough analysis detail to evaluate robustness. Here, the registry lists no analysis entries and does not report the primary outcome values. The absence of those results limits what can be learned from the record, while not implying that an analysis was never performed.

Finally, multiple molecular outcomes create a need for transparent reporting of outcome selection and multiplicity handling. The registry lists 25 outcome measures but does not report a strategy for interpreting them together. That information is important when readers assess whether findings are prespecified, exploratory, or potentially affected by multiple comparisons. The main statistical lesson is that design, endpoint scale, uncertainty, analysis transparency, and multiplicity all shape interpretation; none can be replaced by a study’s rationale alone.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations affect interpretation of the registry record. The allocation is explicitly non-randomized, so treatment sequence cannot be assumed to be balanced by random assignment. Masking is listed as none, leaving possible influence from participant or assessor expectations. The record does not explain how sequences were assigned or whether other design protections were used.

The crossover design makes the handling of repeated measurements central. Although a 3-week washout is specified, the registry does not report whether carryover was assessed, how period or sequence effects were handled, or whether the primary comparison used paired observations. It also does not establish that all enrolled participants completed both intervention periods.

The primary endpoint estimate and confidence interval bounds are absent. The exact statistical model, analysis population, missing-data approach, and any sensitivity analyses are not reported in the registry record. The record lists 25 outcome measures but does not describe multiplicity handling. These omissions prevent an assessment of the precision, robustness, and selection context of any endpoint finding.

The study is described as completed, but completion status does not supply outcome results. Enrollment was 23; the number contributing data to the primary analysis is not reported in the registry record. The scope of interpretation is also limited by the endpoint itself: adipose tissue IL-6 mRNA is a molecular measure and cannot be treated as a direct clinical outcome. These limitations concern what can be concluded from the registry information, not proof that unreported methods or analyses were absent.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response — NCT04387201.
• Registry record last updated 2024-12-05; status last verified 2024-11.
• Results first posted 2024-12-05.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04387201 is a completed Phase 4, non-randomized crossover study with no masking, sponsored by The University of Texas Health Science Center, Houston. Enrollment was 23. The study compared periods of weekly subcutaneous cyanocobalamin and dulaglutide, separated by a 3-week washout. Dulaglutide was given at 0.75 mg weekly for 2 weeks followed by 1.5 mg weekly for 4 weeks; cyanocobalamin was given at 1000 mcg weekly for 6 weeks.

The primary outcome was mean natural log-transformed IL-6 mRNA from adipose tissue, measured 6 weeks after the start of each intervention and specified with a 95% confidence interval. The endpoint estimates, interval bounds, and statistical comparison are not reported in the registry record. The record lists secondary molecular outcomes and group-level adverse-event counts, but does not report an analysis population, missing-data methods, or multiplicity strategy. Consequently, the registry supports a description of the research question and design, but not a conclusion about the primary endpoint response.